Medical Oncology

, Volume 28, Issue 4, pp 1038–1043 | Cite as

TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis

  • Na Wang
  • Quanlin GuanEmail author
  • Kai Wang
  • Bingdong Zhu
  • Wenzhen Yuan
  • Peng Zhao
  • Xiaowei Wang
  • Yongxun Zhao
Original Paper


To assess the evidence for improved outcomes in hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI). A systematic search of MEDLINE, EMBASE, the Cochrane library, Chinese biomedicine literature database, Chinese scientific full-text database, and Chinese journal full-text database was undertaken for relevant articles. The computer search was supplemented with a manual search of reference lists for all available review articles, primary studies, and books to identify other studies not found in the computer search. The initial search identified seven randomized trials that included 623 patients. Meta-analysis results are as follows: the 6-month, 1-, 2-, and 3-year survival rates were significantly better in patients with the TACE + PEI group than TACE group; in the decline rates of the AFP level and the reduction rates of tumor size (>50%), the TACE + PEI group has better effects than TACE group; as adverse effects, TACE + PEI group has lower incidence rates than TACE group. In patients with HCC, the efficacy of TACE combined with PEI is significantly better than that of TACE alone. Although there is convincing evidence to confirm the results mentioned, they still need to be confirmed by large sample, multicenter, randomized, controlled trials.


Hepatocellular carcinoma Chemoembolization Ethanol injection Meta-analysis 


Conflict of interest statement

The authors made no disclosures.


  1. 1.
    Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.PubMedCrossRefGoogle Scholar
  2. 2.
    Samuel M, Chow PK, Chan Shih-Yen E, et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma (Review). The Cochrane Library. 2009, Issue 3.Google Scholar
  3. 3.
    Oliveri RS, Gluud C. Transcatheter arterial embolisation and chemoembolisation for hepatocellular carcinoma (Protocol). The Cochrane Library. 2009; Issue 3.Google Scholar
  4. 4.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.PubMedCrossRefGoogle Scholar
  5. 5.
    Marelli L, Stigliano R, Triantos C, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2006;32:594–606.PubMedCrossRefGoogle Scholar
  6. 6.
    Li HB, Qiu SM. Analysis of combination of hepatic arterial chemoembolization and percutaneous ethanol injection for treatment of primary liver cancer. Med Sci Edi. 2008;27:368–70.Google Scholar
  7. 7.
    Li XY, Yang LZ. Analysis of transcatherter arterial chemoembolization combined with percutaneous ethanol injection for hepatoma. Chin J Interv Imaging Ther. 2007;4:269–72.Google Scholar
  8. 8.
    Zhao XL, Zhao ZJ, Zhou Q, et al. Combination of transcatheter arterial chemoembolization and percutaneous ethanol injection for treatment of huge unresectable hepatocellular carcinoma under ultrasound. J Fourth Mil Med Univ. 2004;25:1382.Google Scholar
  9. 9.
    Kato T, Saito Y, Niwa M, et al. Combination therapy of transcatheter chemienbolization and percutaneous wthanol injection therapy for unresectable hepatocellualar carcinoma. Cancer Chemother Pharmacol. 1994;33:115–8.CrossRefGoogle Scholar
  10. 10.
    Qu ZQ, Qian GJ, Chen H. Therapeutic effect of transcatheter arterial chemoembolization combined with percutaneous ethanol injection in hepatocellular carcinoma. Chinese–German J Clin Oncol. 2002;1:28–9.CrossRefGoogle Scholar
  11. 11.
    Bartolozzi C, Lencioni R, Caramella D, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology. 1995;197:812–8.PubMedGoogle Scholar
  12. 12.
    Becker G, Soezgen T, Olschewski M, et al. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol. 2005;11:6104–9.PubMedGoogle Scholar
  13. 13.
    Liu SB, Hu DY, Huang YY, et al. The double intervention clinical value and application research of TACE with PAI on massive hepatocellular carcinoma. Chinese–German J Clin Oncol. 2008;7:128–30.CrossRefGoogle Scholar
  14. 14.
    Tesdal IK, Wikström M, Flechtenmacher C, et al. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol. 2006;29:778–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Chen XM, Luo PF, Lin HH. Long-term result of combination of transcatheter arterial chemoembolization and percutaneous ethanol injection for treatment of hepatocellular carcinoma. Chin J Cancer. 2004;23:829–32.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Na Wang
    • 1
  • Quanlin Guan
    • 1
    Email author
  • Kai Wang
    • 2
  • Bingdong Zhu
    • 3
  • Wenzhen Yuan
    • 1
  • Peng Zhao
    • 1
  • Xiaowei Wang
    • 1
  • Yongxun Zhao
    • 1
  1. 1.Oncological Surgery of First Hospital of Lanzhou UniversityLanzhouChina
  2. 2.Department of SurgerySecond Hospital of Lanzhou UniversityLanzhouChina
  3. 3.Institute of Pathogenic BiologyLanzhou UniversityLanzhouChina

Personalised recommendations